EMA prepares to issue revised draft biosimilar insulin guideline; market a tough nut to crack as Marvel stumbles again
This article was originally published in SRA
The European Medicines Agency hopes to release the draft revised version of its insulin guideline for consultation within a couple of months, the agency said1 as it announced that Marvel BioSciences, a marketing company for the India-based MJ Biopharm, has hit another hitch in its efforts to get its biosimilar insulin onto the EU market, withdrawing approval applications for three products that were under evaluation by the EMA2.
You may also be interested in...
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.